Figure 3
From: Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
Overall survival. Symbols on the plot indicate censored patients. Analysis excludes the second retreatment for 3 systemic anaplastic large cell lymphoma patients.